Klas Holmlund, Cfa
About Klas Holmlund, Cfa
Klas Holmlund is the Chief Financial Officer at Lyndra Therapeutics, a position he has held since 2021. He has a strong background in finance, with previous roles at Evergreen Investments, Vertex Pharmaceuticals, and General Motors, and holds degrees from Boston College, Lewis & Clark College, and Yale School of Management.
Current Role at Lyndra Therapeutics
Klas Holmlund serves as the Chief Financial Officer at Lyndra Therapeutics, a position he has held since 2021. In this role, he oversees the financial operations of the company, contributing to its strategic financial planning and management. His experience in the biotechnology sector supports Lyndra's mission to develop innovative drug delivery systems. Holmlund's tenure at Lyndra Therapeutics is marked by his focus on enhancing financial performance and ensuring sustainable growth.
Professional Background
Klas Holmlund has extensive experience in finance and treasury management. Prior to joining Lyndra Therapeutics, he worked at Vertex Pharmaceuticals as Head of Treasury from 2010 to 2021, where he managed the company's treasury functions. Before that, he held various treasury roles at General Motors from 2007 to 2010. His career began at Evergreen Investments as an Investment Analyst from 2001 to 2005. This diverse background provides him with a solid foundation in financial strategy and operations.
Education and Qualifications
Klas Holmlund holds multiple degrees that reflect his expertise in finance and economics. He earned a Bachelor of Arts in Economics from Lewis & Clark College. He further advanced his education by obtaining a Master of Business Administration from Yale School of Management. Additionally, he achieved a Master of Science in Finance from Boston College. His academic background supports his professional roles in financial management.
Career Timeline
Klas Holmlund's career spans over two decades, with significant roles in finance and treasury. He began his career at Evergreen Investments as an Investment Analyst from 2001 to 2005. He then transitioned to General Motors, where he worked in various treasury roles from 2007 to 2010. Following this, he spent 11 years at Vertex Pharmaceuticals as Head of Treasury before joining Lyndra Therapeutics in 2021. His career trajectory illustrates a consistent focus on financial leadership.